Cargando…

DMARDs–Gut Microbiota Feedback: Implications in the Response to Therapy

Due to its immunomodulatory effects and the limitation in the radiological damage progression, disease-modifying antirheumatic drugs (DMARDs) work as first-line rheumatoid arthritis (RA) treatment. In recent years, numerous research projects have suggested that the metabolism of DMARDs could have a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaragoza-García, Oscar, Castro-Alarcón, Natividad, Pérez-Rubio, Gloria, Guzmán-Guzmán, Iris Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692063/ https://www.ncbi.nlm.nih.gov/pubmed/33114390 http://dx.doi.org/10.3390/biom10111479

Ejemplares similares

Serum Levels of IFABP2 and Differences in Lactobacillus and Porphyromonas gingivalis Abundance on Gut Microbiota Are Associated with Poor Therapeutic Response in Rheumatoid Arthritis: A Pilot Study
por: Zaragoza-García, Oscar, et al.
Publicado: (2023)

PADI2 Polymorphisms Are Significantly Associated With Rheumatoid Arthritis, Autoantibodies Serologic Status and Joint Damage in Women from Southern Mexico
por: Guzmán-Guzmán, Iris Paola, et al.
Publicado: (2021)

Low Seroprevalence of Measles-Specific IgG in Children of Three Ethnic Groups from Mexico: Influence of Age, Sex, Malnutrition and Family Size
por: Sánchez-Alemán, Miguel A., et al.
Publicado: (2021)

The Infection, Coinfection, and Abundance of Intestinal Protozoa Increase the Serum Levels of IFABP2 and TNF-α in Patients With Rheumatoid Arthritis
por: Guzmán-Guzmán, Iris Paola, et al.
Publicado: (2022)

Outcome predictors in COVID-19: An analysis of emergent systemic inflammation indices in Mexican population
por: Gutiérrez-Pérez, Ilse Adriana, et al.
Publicado: (2022)

Gut Microbiota and Metabolic Endotoxemia in Young Obese Mexican Subjects
por: Radilla-Vázquez, Romina Belén, et al.
Publicado: (2016)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Emergent Anthropometric Indices in Differential Prediction of Prehypertension and Hypertension in Mexican Population: Results according to Age and Sex
por: Zaragoza-García, Oscar, et al.
Publicado: (2022)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy
por: Galarza-Delgado, Dionicio Ángel, et al.
Publicado: (2020)

Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?
por: Machold, Klaus P, et al.
Publicado: (2006)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Impact of access to treatment on patient‐reported outcomes among rheumatoid arthritis patients with tDMARDs and bDMARDS in two Latin‐American countries: A prospective observational study
por: Reyes, Juan M., et al.
Publicado: (2023)

Gut Microbiota and Parkinson’s Disease: Implications for Faecal Microbiota Transplantation Therapy
por: Kang, Yongbo, et al.
Publicado: (2021)

A history of the term “DMARD”
por: Buer, Jonas Kure
Publicado: (2015)

Is symptom duration before DMARD therapy a determinant of direct and indirect costs in DMARD-naïve RA patients? A systematic review
por: Sahbudin, Ilfita, et al.
Publicado: (2023)

Functional roles of the microbiota-gut-brain axis in Alzheimer’s disease: Implications of gut microbiota-targeted therapy
por: Zhong, Si-Ran, et al.
Publicado: (2021)

Gut microbiota and its implications for psychiatry
por: Ochoa, A. Matas, et al.
Publicado: (2021)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

IFNAR2 relevance in the clinical outcome of individuals with severe COVID-19
por: Fricke-Galindo, Ingrid, et al.
Publicado: (2022)

Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone
por: Edwards, Carl K., et al.
Publicado: (2012)

Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion
por: Marasco, Emiliano, et al.
Publicado: (2023)

The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice
por: Roberts, Lynden, et al.
Publicado: (2017)

Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
por: De La Fuente, Fanny, et al.
Publicado: (2022)

Implication of Gut Microbiota in Cardiovascular Diseases
por: Zhou, Wenyi, et al.
Publicado: (2020)

Gut Microbiota: Implications in Alzheimer’s Disease
por: He, Yixi, et al.
Publicado: (2020)

Gut microbiota: Implications in Parkinson's disease
por: Parashar, Arun, et al.
Publicado: (2017)

Implications of Gut Microbiota in Neurodegenerative Diseases
por: Zhang, Haoming, et al.
Publicado: (2022)

COVID-19 Survivor Patients Carrying the Rs35705950 Risk Allele in MUC5B Have Higher Plasma Levels of Mucin 5B
por: García-Carmona, Salvador, et al.
Publicado: (2022)

A Blood Protein Signature Stratifies Clinical Response to csDMARD Therapy in Pediatric Uveitis
por: Wennink, Roos A. W., et al.
Publicado: (2022)

Are DMARDs enough to prevent surgery in rheumatoid hands?
por: Sim, Yeap Swan
Publicado: (2015)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial
por: Hebing, Renske CF, et al.
Publicado: (2022)

Interaction of dietary fat intake with APOA2, APOA5 and LEPR polymorphisms and its relationship with obesity and dyslipidemia in young subjects
por: Domínguez-Reyes, Teresa, et al.
Publicado: (2015)

Enteroaggregative Escherichia coli is associated with antibiotic resistance and urinary tract infection symptomatology
por: Martínez-Santos, Verónica I., et al.
Publicado: (2021)

Gut Microbiota and Their Neuroinflammatory Implications in Alzheimer’s Disease
por: Giau, Vo Van, et al.
Publicado: (2018)

Dysbiosis and Implication of the Gut Microbiota in Diabetic Retinopathy
por: Huang, Yinhua, et al.
Publicado: (2021)

Implications of Gut Microbiota in Complex Human Diseases
por: Yu, Dahai, et al.
Publicado: (2021)

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
por: Kremer, Joel M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tv51vocc0as1jcajdu0fe1in32